Renal Failure

Onconephrology Update: Emerging Insights and Evolving Practice

Breakthroughs in cancer treatment have improved long-term outcomes of patients with various malignancies. However, cancer and antineoplastic therapies can affect the kidney throughin various pathophysiological mechanisms, leading to acute kidney injury, chronic kidney disease, electrolyte and acid base abnormalities and proteinuria. These effects paved the way for the inception and evolution of the “Onconephrology” discipline, a captivating subspecialty of Nephrology, emerging from the intersection of Cancer and Kidney Disease.

With advancements in the treatment of cancer, nephrologists are becoming core members of the care team of patients with malignancies. Onconephrology equips nephrologists with the information and tools needed to understand the mechanistic pathophysiological mechanisms of kidney affection in cancer patients, the necessary diagnostic workup and available treatment options, to help improve outcomes in this patient population. Moreover, many novel anti-neoplastic therapies require medication dosing in patients with chronic kidney disease, making this onconephrology a core subspecialty of nephrology.

This collection will encompass the following topics:

• Acute Kidney Injury in Cancer Patients
• Nephrotoxic Effects of Traditional Chemotherapeutic Agents
• Immunotherapy (Immune Checkpoint Inhibitor + CAR-T cell Rx + Bispecific antibodies) Associated Kidney Disease
• Electrolyte Abnormalities in Patients with Cancer
• Targeted Therapies and Kidney Toxicity
• Paraprotein-Mediated Kidney Disease
• chronic kidney disease in Cancer Survivors
• Paraneoplastic Glomerulopathies
• Pregnancy, Cancer and Kidney Disease
• Kidney Transplantation and Cancer
• Anemia in Patients with Cancer
• Hypertension in patients with cancer (Oncohypertension)
• Pediatric to adult transition of cancer survivorship
• Thrombotic microangiopathy in patients with cancer
• Biomarkers and AI applications in onco-nephrology
• GFR estimation and drug dosing in cancer patients with kidney disease
• Kidney disease in patients with hematopoietic stem cell transplantation

Article Collection key terms:

• Onconephrology
• Cancer
• Malignancy
• Kidney Injury
• Anti-Neoplastic agents.

Article Collection Guest Advisors:

Dr. Mohamed H. Hassanein is a double American Board Certified onconephrologist in Alexandria, Egypt. He received his medical degree from Alexandria University. Following that, he completed his Internal medicine and Nephrology fellowship at Michigan State University and the Cleveland Clinic Foundation, before joining the University of Mississippi Medical Center as an Assistant Professor of Medicine. He is a member of the Educational Committee of the American Society of Onconephrology.

Dr. Prakash S. Gudsoorkar is an Associate Professor of Medicine in the Division of Nephrology at the University of Cincinnati Medical Center and an attending nephrologist at UC Health. He serves on the editorial board of Advances in Kidney Health and Disease and as Deputy Editor of Kidney News, the flagship publication of the American Society of Nephrology. He serves on the board of directors for the Renal Physicians Association. As the medical lead and director of the Onconephrology Service within UC Health’s Cancer Survivorship Program, Dr. Gudsoorkar is helping build comprehensive, integrated models of care for patients navigating the intersecting challenges of cancer and kidney disease. His research focuses on chemotherapy-induced nephrotoxicity, renal complications of immunotherapy, and targeted therapy–associated hypertension. He is also deeply committed to advancing home dialysis by expanding access, enhancing patient experience, and improving clinical outcomes.

Dr. Paul Hanna earned his medical degree from the Medical College of Wisconsin in 2017 and completed his nephrology fellowship at Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School. He subsequently pursued subspecialty training in onconephrology at the Dana-Farber Cancer Institute in Boston and advanced glomerulonephritis training through the GlomCon Virtual program. He currently serves as Assistant Professor of Medicine at Mayo Clinic in Jacksonville, Florida.

Dr. Sabine Karam obtained her medical degree from Faculté de Médecine- Université Saint-Joseph in Beirut, Lebanon followed by an internal medicine residency at Albert Einstein College of Medicine/ Montefiore Medical Center, Bronx, New York, and a Nephrology fellowship at the George Washington University Hospital in Washington, DC. She is currently an associate professor of medicine in the division of Nephrology and Hypertension at the University of Minnesota and an adjunct faculty at the American University of Beirut, Lebanon. She is passionate about serving the scientific community and in that regard, she serves on several committees at the International Society of Nephrology, the American Society of Onco-nephrology where she is a member of the executive board and the current Secretary, the National Kidney Foundation- Minnesota chapter and the French Speaking society of Nephrology (Société Francophone de Néphrologie, Dialyse, et Transplantation (SFNDT))

Dr. Omar Mamlouk joined MD Anderson in 2019, beginning as an onco-nephrology fellow before transitioning to a faculty position. He earned his medical degree from the Jordan University of Science and Technology and completed his postgraduate training at the University of Texas McGovern Medical School. Dr. Mamlouk’s clinical expertise focuses on onco-nephrology, specifically immunotherapy nephrotoxicity (including checkpoint inhibitors and CAR T-cell therapies) and stem cell- related thrombotic microangiopathy. His primary research investigates the epidemiology and treatment of checkpoint inhibitor-related nephrotoxicity

­­All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 12th March 2027.

Please contact Rebecca Kearns at [email protected] with any queries and discount codes regarding this Article Collection.

Please be sure to select the appropriate Article Collection from the drop-down menu in the submission system.

The Guest Advisors for this Article Collection have declared no conflict of interests